Ocular Therapeutix (OCUL) Projected to Release Quarterly Earnings on Tuesday

Ocular Therapeutix (NASDAQ:OCUL) will likely be releasing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.3635) per share and revenue of $14.27 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.05. Ocular Therapeutix had a negative net margin of 579.10% and a negative return on equity of 59.89%. The company had revenue of $13.47 million for the quarter, compared to the consensus estimate of $13.20 million. During the same period in the prior year, the firm posted ($0.39) EPS. The firm’s revenue was down .1% compared to the same quarter last year. On average, analysts expect Ocular Therapeutix to post ($1.47) EPS for the current fiscal year and ($1.35) EPS for the next fiscal year.

Ocular Therapeutix Stock Down 0.5%

NASDAQ:OCUL opened at $6.47 on Tuesday. The company has a market cap of $1.42 billion, a price-to-earnings ratio of -4.56 and a beta of 1.00. Ocular Therapeutix has a twelve month low of $6.00 and a twelve month high of $16.44. The stock has a fifty day simple moving average of $9.14 and a 200-day simple moving average of $9.21. The company has a current ratio of 13.10, a quick ratio of 13.03 and a debt-to-equity ratio of 0.14.

Insider Transactions at Ocular Therapeutix

In other Ocular Therapeutix news, insider Jeffrey Heier sold 10,869 shares of the firm’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $7.05, for a total value of $76,626.45. Following the transaction, the insider owned 307,457 shares in the company, valued at approximately $2,167,571.85. This trade represents a 3.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Pravin Dugel sold 21,649 shares of the firm’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $10.77, for a total transaction of $233,159.73. Following the completion of the transaction, the insider directly owned 2,525,429 shares in the company, valued at approximately $27,198,870.33. This represents a 0.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 62,720 shares of company stock valued at $556,247 in the last 90 days. 3.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Ocular Therapeutix in a research report on Tuesday, October 20th. Zacks Research raised shares of Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Ocular Therapeutix in a research note on Tuesday, September 29th. Chardan Capital restated a “buy” rating and issued a $23.00 target price on shares of Ocular Therapeutix in a research note on Friday, October 2nd. Finally, UBS Group started coverage on shares of Ocular Therapeutix in a research note on Sunday, October 11th. They set a “buy” rating and a $14.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $22.86.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc (NASDAQ:OCUL) is a biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company uses its proprietary hydrogel-based drug-delivery technology to provide sustained or controlled release of medicines in ophthalmic applications.

Its commercial products include Dextenza, a dexamethasone ophthalmic insert used to treat ocular inflammation and itching following ophthalmic surgery, and Yutiq, a fluocinolone acetonide intravitreal implant indicated for the treatment of chronic noninfectious posterior uveitis.